Cargando…
Increased Risk of Urticaria/Angioedema after BNT162b2 mRNA COVID-19 Vaccine in Health Care Workers Taking ACE Inhibitors
Urticarial eruptions and angioedema are the most common cutaneous reactions in patients undergoing mRNA COVID-19 vaccinations. The vasoactive peptide bradykinin has long been known to be involved in angioedema and recently also in urticaria. Bradykinin is mainly catabolized by angiotensin-converting...
Autores principales: | , , , , , , , , , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473401/ https://www.ncbi.nlm.nih.gov/pubmed/34579248 http://dx.doi.org/10.3390/vaccines9091011 |
_version_ | 1784574982723993600 |
---|---|
author | Cugno, Massimo Consonni, Dario Lombardi, Andrea Bono, Patrizia Oggioni, Massimo Uceda Renteria, Sara Pesatori, Angela Cecilia Castaldi, Silvana Riboldi, Luciano Bordini, Lorenzo Nava, Carlo Domenico Ceriotti, Ferruccio Torri, Adriana Tafuri, Francesco Ghigliazza, Gabriele Peyvandi, Flora Bandera, Alessandra Gori, Andrea |
author_facet | Cugno, Massimo Consonni, Dario Lombardi, Andrea Bono, Patrizia Oggioni, Massimo Uceda Renteria, Sara Pesatori, Angela Cecilia Castaldi, Silvana Riboldi, Luciano Bordini, Lorenzo Nava, Carlo Domenico Ceriotti, Ferruccio Torri, Adriana Tafuri, Francesco Ghigliazza, Gabriele Peyvandi, Flora Bandera, Alessandra Gori, Andrea |
author_sort | Cugno, Massimo |
collection | PubMed |
description | Urticarial eruptions and angioedema are the most common cutaneous reactions in patients undergoing mRNA COVID-19 vaccinations. The vasoactive peptide bradykinin has long been known to be involved in angioedema and recently also in urticaria. Bradykinin is mainly catabolized by angiotensin-converting enzyme (ACE), which is inhibited by ACE inhibitors, a commonly employed class of antihypertensive drugs. We evaluated the risk of developing urticaria/angioedema after inoculation with the BNT162b2 mRNA COVID-19 vaccine in a population of 3586 health care workers. The influences of ACE inhibitors and selected potential confounding variables (sex, age, previous SARS-CoV-2 infection, and allergy history) were evaluated by fitting univariate and multivariable Poisson regression models. The overall cumulative incidence of urticaria/angioedema was 1.8% (65 out of 3586; 95% CI: 1.4–2.3%). Symptoms were mild, and no subject consulted a physician. Subjects taking ACE inhibitors had an adjusted three-fold increased risk of urticaria/angioedema (RR 2.98, 95% CI: 1.12–7.96). When we restricted the analysis to those aged 50 years or more, the adjusted RR was 3.98 (95% CI: 1.44–11.0). In conclusion, our data indicate that subjects taking ACE inhibitors have an increased risk of urticaria/angioedema after vaccination with the BNT162b2 mRNA COVID-19 vaccine. Symptoms are mild and self-limited; however, they should be considered to adequately advise subjects undergoing vaccination. |
format | Online Article Text |
id | pubmed-8473401 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-84734012021-09-28 Increased Risk of Urticaria/Angioedema after BNT162b2 mRNA COVID-19 Vaccine in Health Care Workers Taking ACE Inhibitors Cugno, Massimo Consonni, Dario Lombardi, Andrea Bono, Patrizia Oggioni, Massimo Uceda Renteria, Sara Pesatori, Angela Cecilia Castaldi, Silvana Riboldi, Luciano Bordini, Lorenzo Nava, Carlo Domenico Ceriotti, Ferruccio Torri, Adriana Tafuri, Francesco Ghigliazza, Gabriele Peyvandi, Flora Bandera, Alessandra Gori, Andrea Vaccines (Basel) Brief Report Urticarial eruptions and angioedema are the most common cutaneous reactions in patients undergoing mRNA COVID-19 vaccinations. The vasoactive peptide bradykinin has long been known to be involved in angioedema and recently also in urticaria. Bradykinin is mainly catabolized by angiotensin-converting enzyme (ACE), which is inhibited by ACE inhibitors, a commonly employed class of antihypertensive drugs. We evaluated the risk of developing urticaria/angioedema after inoculation with the BNT162b2 mRNA COVID-19 vaccine in a population of 3586 health care workers. The influences of ACE inhibitors and selected potential confounding variables (sex, age, previous SARS-CoV-2 infection, and allergy history) were evaluated by fitting univariate and multivariable Poisson regression models. The overall cumulative incidence of urticaria/angioedema was 1.8% (65 out of 3586; 95% CI: 1.4–2.3%). Symptoms were mild, and no subject consulted a physician. Subjects taking ACE inhibitors had an adjusted three-fold increased risk of urticaria/angioedema (RR 2.98, 95% CI: 1.12–7.96). When we restricted the analysis to those aged 50 years or more, the adjusted RR was 3.98 (95% CI: 1.44–11.0). In conclusion, our data indicate that subjects taking ACE inhibitors have an increased risk of urticaria/angioedema after vaccination with the BNT162b2 mRNA COVID-19 vaccine. Symptoms are mild and self-limited; however, they should be considered to adequately advise subjects undergoing vaccination. MDPI 2021-09-11 /pmc/articles/PMC8473401/ /pubmed/34579248 http://dx.doi.org/10.3390/vaccines9091011 Text en © 2021 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Brief Report Cugno, Massimo Consonni, Dario Lombardi, Andrea Bono, Patrizia Oggioni, Massimo Uceda Renteria, Sara Pesatori, Angela Cecilia Castaldi, Silvana Riboldi, Luciano Bordini, Lorenzo Nava, Carlo Domenico Ceriotti, Ferruccio Torri, Adriana Tafuri, Francesco Ghigliazza, Gabriele Peyvandi, Flora Bandera, Alessandra Gori, Andrea Increased Risk of Urticaria/Angioedema after BNT162b2 mRNA COVID-19 Vaccine in Health Care Workers Taking ACE Inhibitors |
title | Increased Risk of Urticaria/Angioedema after BNT162b2 mRNA COVID-19 Vaccine in Health Care Workers Taking ACE Inhibitors |
title_full | Increased Risk of Urticaria/Angioedema after BNT162b2 mRNA COVID-19 Vaccine in Health Care Workers Taking ACE Inhibitors |
title_fullStr | Increased Risk of Urticaria/Angioedema after BNT162b2 mRNA COVID-19 Vaccine in Health Care Workers Taking ACE Inhibitors |
title_full_unstemmed | Increased Risk of Urticaria/Angioedema after BNT162b2 mRNA COVID-19 Vaccine in Health Care Workers Taking ACE Inhibitors |
title_short | Increased Risk of Urticaria/Angioedema after BNT162b2 mRNA COVID-19 Vaccine in Health Care Workers Taking ACE Inhibitors |
title_sort | increased risk of urticaria/angioedema after bnt162b2 mrna covid-19 vaccine in health care workers taking ace inhibitors |
topic | Brief Report |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8473401/ https://www.ncbi.nlm.nih.gov/pubmed/34579248 http://dx.doi.org/10.3390/vaccines9091011 |
work_keys_str_mv | AT cugnomassimo increasedriskofurticariaangioedemaafterbnt162b2mrnacovid19vaccineinhealthcareworkerstakingaceinhibitors AT consonnidario increasedriskofurticariaangioedemaafterbnt162b2mrnacovid19vaccineinhealthcareworkerstakingaceinhibitors AT lombardiandrea increasedriskofurticariaangioedemaafterbnt162b2mrnacovid19vaccineinhealthcareworkerstakingaceinhibitors AT bonopatrizia increasedriskofurticariaangioedemaafterbnt162b2mrnacovid19vaccineinhealthcareworkerstakingaceinhibitors AT oggionimassimo increasedriskofurticariaangioedemaafterbnt162b2mrnacovid19vaccineinhealthcareworkerstakingaceinhibitors AT ucedarenteriasara increasedriskofurticariaangioedemaafterbnt162b2mrnacovid19vaccineinhealthcareworkerstakingaceinhibitors AT pesatoriangelacecilia increasedriskofurticariaangioedemaafterbnt162b2mrnacovid19vaccineinhealthcareworkerstakingaceinhibitors AT castaldisilvana increasedriskofurticariaangioedemaafterbnt162b2mrnacovid19vaccineinhealthcareworkerstakingaceinhibitors AT riboldiluciano increasedriskofurticariaangioedemaafterbnt162b2mrnacovid19vaccineinhealthcareworkerstakingaceinhibitors AT bordinilorenzo increasedriskofurticariaangioedemaafterbnt162b2mrnacovid19vaccineinhealthcareworkerstakingaceinhibitors AT navacarlodomenico increasedriskofurticariaangioedemaafterbnt162b2mrnacovid19vaccineinhealthcareworkerstakingaceinhibitors AT ceriottiferruccio increasedriskofurticariaangioedemaafterbnt162b2mrnacovid19vaccineinhealthcareworkerstakingaceinhibitors AT torriadriana increasedriskofurticariaangioedemaafterbnt162b2mrnacovid19vaccineinhealthcareworkerstakingaceinhibitors AT tafurifrancesco increasedriskofurticariaangioedemaafterbnt162b2mrnacovid19vaccineinhealthcareworkerstakingaceinhibitors AT ghigliazzagabriele increasedriskofurticariaangioedemaafterbnt162b2mrnacovid19vaccineinhealthcareworkerstakingaceinhibitors AT peyvandiflora increasedriskofurticariaangioedemaafterbnt162b2mrnacovid19vaccineinhealthcareworkerstakingaceinhibitors AT banderaalessandra increasedriskofurticariaangioedemaafterbnt162b2mrnacovid19vaccineinhealthcareworkerstakingaceinhibitors AT goriandrea increasedriskofurticariaangioedemaafterbnt162b2mrnacovid19vaccineinhealthcareworkerstakingaceinhibitors |